Ushering an antibody cocktail, designed to reduce antibody resistance, to trial as COVID-19 therapy

Following two studies that screened thousands of human antibodies to SARS-CoV-2 to identify highly potent pairs, in which the antibodies bind non-overlapping regions of the viral target, a resultant antibody cocktail is being tested in human trials.